med.stanford.edu/cancer/abo...
« The fast-track clinical trial is a phase I, first-in-human study evaluating a drug called INCB160058. This drug inhibits only the JAK2 V617F mutation without targeting the normal JAK2 gene. The study protocol initially evaluates drug tolerability and safety to identify the highest dose patients can tolerate without severe side effects. Once the right dose is identified, the study investigators hope that INCB160058 will be more effective and safe compared to the currently available JAK inhibitors used to treat myelofibrosis.
Gotlib ultimately hopes that this second generation of more highly targeted drugs, such as INCB160058, can be paired in future clinical trials with drugs that have different mechanisms to improve the survival of patients with these rare, poor-risk hematologic malignancies.
Stanford has treated four patients on the protocol and several more individuals have been identified for screening. Additional study sites have recently opened in the United States. The study is being conducted with the study sponsor Incyte Corporation, manufacturer of INCB160058.